Logo image of AEZS

AETERNA ZENTARIS INC (AEZS) Stock Fundamental Analysis

NASDAQ:AEZS - Nasdaq - CA0079756007 - Common Stock - Currency: USD

5.72  +0.32 (+5.93%)

Fundamental Rating

1

AEZS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. AEZS has a bad profitability rating. Also its financial health evaluation is rather negative. AEZS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AEZS has reported negative net income.
AEZS had a negative operating cash flow in the past year.
In the past 5 years AEZS always reported negative net income.
AEZS had a negative operating cash flow in each of the past 5 years.
AEZS Yearly Net Income VS EBIT VS OCF VS FCFAEZS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M -50M

1.2 Ratios

AEZS has a Return On Assets (-56.80%) which is in line with its industry peers.
AEZS has a worse Return On Equity (-139.22%) than 62.76% of its industry peers.
Industry RankSector Rank
ROA -56.8%
ROE -139.22%
ROIC N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEZS Yearly ROA, ROE, ROICAEZS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

Looking at the Gross Margin, with a value of 90.69%, AEZS belongs to the top of the industry, outperforming 93.18% of the companies in the same industry.
AEZS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AEZS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
AEZS Yearly Profit, Operating, Gross MarginsAEZS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

AEZS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AEZS has been reduced compared to 1 year ago.
AEZS has more shares outstanding than it did 5 years ago.
AEZS has a worse debt/assets ratio than last year.
AEZS Yearly Shares OutstandingAEZS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
AEZS Yearly Total Debt VS Total AssetsAEZS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -16.76, we must say that AEZS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -16.76, AEZS is not doing good in the industry: 85.49% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that AEZS is not too dependend on debt financing.
The Debt to Equity ratio of AEZS (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -16.76
ROIC/WACCN/A
WACC10.12%
AEZS Yearly LT Debt VS Equity VS FCFAEZS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 5.94 indicates that AEZS has no problem at all paying its short term obligations.
AEZS has a Current ratio of 5.94. This is comparable to the rest of the industry: AEZS outperforms 59.09% of its industry peers.
AEZS has a Quick Ratio of 5.93. This indicates that AEZS is financially healthy and has no problem in meeting its short term obligations.
AEZS has a Quick ratio (5.93) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.94
Quick Ratio 5.93
AEZS Yearly Current Assets VS Current LiabilitesAEZS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

AEZS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -274.15%.
Looking at the last year, AEZS shows a very negative growth in Revenue. The Revenue has decreased by -62.06% in the last year.
AEZS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.07% yearly.
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.43%
Revenue 1Y (TTM)-62.06%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%-99.81%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEZS Yearly Revenue VS EstimatesAEZS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AEZS Yearly EPS VS EstimatesAEZS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AEZS. In the last year negative earnings were reported.
Also next year AEZS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEZS Price Earnings VS Forward Price EarningsAEZS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEZS Per share dataAEZS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AEZS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AETERNA ZENTARIS INC

NASDAQ:AEZS (8/8/2024, 8:00:00 PM)

5.72

+0.32 (+5.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-07 2024-11-07/bmo
Inst Owners0.81%
Inst Owner Change11.72%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.51M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.37
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-11
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-5.67
FCFYN/A
OCF(TTM)-5.67
OCFYN/A
SpS0.78
BVpS4.24
TBVpS4.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.8%
ROE -139.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.69%
FCFM N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
F-Score1
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.87%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.94
Quick Ratio 5.93
Altman-Z -16.76
F-Score1
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)148.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.43%
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-62.06%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%-99.81%
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.97%
OCF growth 3YN/A
OCF growth 5YN/A